# Use of Tinzaparin for Anticoagulation in Hemodialysis

Study · id `cardio:ct-nct01930396` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01930396](<https://clinicaltrials.gov/study/NCT01930396>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01930396

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 191 participants.

## Technical summary

Registry record NCT01930396. Randomized; quadruple masking; primary purpose prevention. Start 2013-09 (registry gives no type); primary completion 2016-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 191 participants (enrolled count; ClinicalTrials.gov record NCT01930396, source copy `cardio:ctgov-nct01930396-2016-10-14`, retrieved 2026-10-26)
- Start date: 2013-09 (registry gives no type) (ClinicalTrials.gov record NCT01930396, source copy `cardio:ctgov-nct01930396-2016-10-14`, retrieved 2026-10-26)
- Primary completion: 2016-09 (actual) (ClinicalTrials.gov record NCT01930396, source copy `cardio:ctgov-nct01930396-2016-10-14`, retrieved 2026-10-26)
- Completion: 2016-09 (actual) (ClinicalTrials.gov record NCT01930396, source copy `cardio:ctgov-nct01930396-2016-10-14`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT01930396, source copy `cardio:ctgov-nct01930396-2016-10-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01930396-2016-10-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Use of Tinzaparin for Anticoagulation in Hemodialysis
- Acronym: HEMO-TIN
- Condition: Kidney Failure, Chronic
- Intervention (Drug): Tinzaparin
- Intervention (Drug): Unfractionated Heparin
- Intervention (Drug): Placebo (for Tinzaparin)
- Intervention (Drug): Placebo (for Unfractionated Heparin)
- Lead sponsor: Christine Ribic
- Lead sponsor class: OTHER
- Collaborator: McMaster University
- Collaborator class: OTHER
- Collaborator: LEO Pharma
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record: Heparins and low-molecular-weight heparins (`cardio:heparins-and-low-molecular-weight-heparins`)
- Registry lists this organization as a collaborator: McMaster University (`cardio:org-mcmaster-university`)

## Provenance

Content hash: 8e5c4b0e45471b9b981832394da570d5da475e830199b9da2928bcb9eca7e4f1
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
